mgmt methylation data Search Results


chi-squared test  (CH Instruments)
90
CH Instruments chi-squared test
Chi Squared Test, supplied by CH Instruments, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mgmt+methylation+data/chi+square+test/pmc10802164-156-10-73
Average 90 stars, based on 1 article reviews
chi-squared test - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
methylated mgmt  (Novus Biologicals)
93
Novus Biologicals methylated mgmt
Differential distribution of molecular alterations between A/G and A/A groups of ( a ) all gliomas, ( b ) WHO grade-II oligodendrogliomas with IDH mutation, 1p/19q-codeletion and lack of ATRX mutations, ( c ) WHO grade-II astrocytomas with IDH mutation and ATRX mutations, were plotted as radar graphs. ATRX, p53, p16, PTEN, EGFR and <t>MGMT</t> status was determined by immunohistochemical staining of FFPE-sections. An arbitrary level of 30% was used to determine MGMT promoter methylation. IDH1/2 and TERT promoter mutations were detected by PCR and Sanger sequencing of target region or by “mini-sequencing”. PDGFs indicates copy number gain in any of PDGFA, PDGFB, PDGFRA or PDGFRB, determined by exome sequencing. Number of samples analyzed for each alteration are indicated at the corners of the radar graph in blue (A/A) and red (A/G, G/G). Differential distribution of each molecular alteration between A/G and A/A groups of tumors was determined by chi-square test. y-axis indicates percentage of samples with alteration. (*) Indicates a significance level of p < 0.05; (**) indicates a significance level of p < 0.01. LOE: loss-of-expression; NE: nuclear-expression; TERTp: TERT promoter.
Methylated Mgmt, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mgmt+methylation+data/MGMT+Antibody+(MT+23%2E2)+-+BSA+Free/pmc04901315-218-99-105
Average 93 stars, based on 1 article reviews
methylated mgmt - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier
mgmt methylation data  (Pyrosequencing Inc)
86
Pyrosequencing Inc mgmt methylation data
Differential distribution of molecular alterations between A/G and A/A groups of ( a ) all gliomas, ( b ) WHO grade-II oligodendrogliomas with IDH mutation, 1p/19q-codeletion and lack of ATRX mutations, ( c ) WHO grade-II astrocytomas with IDH mutation and ATRX mutations, were plotted as radar graphs. ATRX, p53, p16, PTEN, EGFR and <t>MGMT</t> status was determined by immunohistochemical staining of FFPE-sections. An arbitrary level of 30% was used to determine MGMT promoter methylation. IDH1/2 and TERT promoter mutations were detected by PCR and Sanger sequencing of target region or by “mini-sequencing”. PDGFs indicates copy number gain in any of PDGFA, PDGFB, PDGFRA or PDGFRB, determined by exome sequencing. Number of samples analyzed for each alteration are indicated at the corners of the radar graph in blue (A/A) and red (A/G, G/G). Differential distribution of each molecular alteration between A/G and A/A groups of tumors was determined by chi-square test. y-axis indicates percentage of samples with alteration. (*) Indicates a significance level of p < 0.05; (**) indicates a significance level of p < 0.01. LOE: loss-of-expression; NE: nuclear-expression; TERTp: TERT promoter.
Mgmt Methylation Data, supplied by Pyrosequencing Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mgmt+methylation+data/data+methylation+pyrosequencing/10__1111_slash_nan__12955-99-17-16
Average 86 stars, based on 1 article reviews
mgmt methylation data - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier

Image Search Results


Differential distribution of molecular alterations between A/G and A/A groups of ( a ) all gliomas, ( b ) WHO grade-II oligodendrogliomas with IDH mutation, 1p/19q-codeletion and lack of ATRX mutations, ( c ) WHO grade-II astrocytomas with IDH mutation and ATRX mutations, were plotted as radar graphs. ATRX, p53, p16, PTEN, EGFR and MGMT status was determined by immunohistochemical staining of FFPE-sections. An arbitrary level of 30% was used to determine MGMT promoter methylation. IDH1/2 and TERT promoter mutations were detected by PCR and Sanger sequencing of target region or by “mini-sequencing”. PDGFs indicates copy number gain in any of PDGFA, PDGFB, PDGFRA or PDGFRB, determined by exome sequencing. Number of samples analyzed for each alteration are indicated at the corners of the radar graph in blue (A/A) and red (A/G, G/G). Differential distribution of each molecular alteration between A/G and A/A groups of tumors was determined by chi-square test. y-axis indicates percentage of samples with alteration. (*) Indicates a significance level of p < 0.05; (**) indicates a significance level of p < 0.01. LOE: loss-of-expression; NE: nuclear-expression; TERTp: TERT promoter.

Journal: Scientific Reports

Article Title: IDH-mutant glioma specific association of rs55705857 located at 8q24.21 involves MYC deregulation

doi: 10.1038/srep27569

Figure Lengend Snippet: Differential distribution of molecular alterations between A/G and A/A groups of ( a ) all gliomas, ( b ) WHO grade-II oligodendrogliomas with IDH mutation, 1p/19q-codeletion and lack of ATRX mutations, ( c ) WHO grade-II astrocytomas with IDH mutation and ATRX mutations, were plotted as radar graphs. ATRX, p53, p16, PTEN, EGFR and MGMT status was determined by immunohistochemical staining of FFPE-sections. An arbitrary level of 30% was used to determine MGMT promoter methylation. IDH1/2 and TERT promoter mutations were detected by PCR and Sanger sequencing of target region or by “mini-sequencing”. PDGFs indicates copy number gain in any of PDGFA, PDGFB, PDGFRA or PDGFRB, determined by exome sequencing. Number of samples analyzed for each alteration are indicated at the corners of the radar graph in blue (A/A) and red (A/G, G/G). Differential distribution of each molecular alteration between A/G and A/A groups of tumors was determined by chi-square test. y-axis indicates percentage of samples with alteration. (*) Indicates a significance level of p < 0.05; (**) indicates a significance level of p < 0.01. LOE: loss-of-expression; NE: nuclear-expression; TERTp: TERT promoter.

Article Snippet: Tumor samples were evaluated by one single neuropathologist and immunohistochemistry (IHC) was performed with antibodies against ATRX (Cat.# HPA001906, Sigma-Aldrich, Steinheim, Germany), p53 (Clone# DO-7, Cat.# A00021-IFU, ScyTek Laboratories, Logan, UT), PTEN (Clone# 17.A, Cat.# MS-1601, Thermo Fisher Scientific, Fremont, CA), p16 INK4A (Clone# E6H4, Cat.# 725-4713, CINtec p16 Histology, Roche Ventana, Basel, Switzerland), EGFR (Clone# EGFR.113, Cat.# NCL-L-EGFR, NovocastraTM Liquid Mouse Monoclonal Ab, Leica Biosystems Newcastle Ltd., Newcastle, UK), IDH1-R132H (Clone# H09, Cat.# DIA-H09, Dianova GmbH, Hamburg, Germany), Ki-67 (Clone# MIB-1, Cat.# M7240, Dako Denmark A/S, Glostrup, Denmark), MYC (Clone# Y69, Cat.# 790-4628, Roche Ventana, Basel, Switzerland) and methylated MGMT (Clone# MT23.2, Cat.# NB100-168, Novus Biologicals, Cambridge, UK), as described before .

Techniques: Mutagenesis, Immunohistochemical staining, Staining, Methylation, Sequencing, Expressing